Policy
Maintaining America’s momentum demands that policymakers resist policies that undermine research and development incentives.
FEATURED STORIES
The current state of political affairs in the U.S. does not bode well for the direction of that turn. The country is at real risk of losing its long-held lead in biotech innovation.
Bristol Myers Squibb, GSK and Merck are contributing drug ingredients as part of their deals with the White House but are keeping many of the terms of their agreements private.
Some 200 rare disease therapies are at risk of losing eligibility for a pediatric priority review voucher, a recent analysis by the Rare Disease Company Coalition shows. That could mean $4 billion in missed revenue for already cash-strapped biotechs.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
A recent report suggests that cross-contamination is not all that uncommon of an issue, and maybe inevitable.
In a filing with the U.S. Securities and Exchange Commission earlier this month, Rosenbaum and his investment group nominated five directors to elect the CytoDyn board.
A vaccine for herpes is under development and Rational Vaccines are going to make this a reality very soon. Here’s everything you need to learn about it.
Novartis claimed the patents held by Plexxikon were invalid. Unfortunately for the company, the jury found it was unable to prove these claims.
As COVID-19 begins yet another surge across the U.S., there is some promising news about the effectiveness of vaccines. Here’s a look at some top COVID-19 stories.
Total payment amounts are contingent on the number of governments that will agree to suspend their lawsuits as part of the deal.
WHO Investigators have attempted to return to the Wuhan lab to find the origins of the novel coronavirus but are now being blocked by the Chinese government.
The U.S. Food and Drug Administration has recently granted Breakthrough Device Designation to two medical device companies, with California-based healthcare tech company Endologix leading the mix.
Biogen’s Aduhelm was approved on June 7, 2021, for Alzheimer’s patients, and the controversy continues to grow.
Notably, Koselugo was studied in pediatric populations first, a reversal of the typical development path taken by the majority of drugs.